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Abstract
Background: Novel Influenza A (H1N1) is an acute respiratory infectious disease. Animal experiments indicated that
when H1N1 virus infected early hosts, it showed strong CD4
+, CD8
+, and CD4
+CD25
+ T cell reactions. The aim of
this study was to investigate the dynamic fluctuations of the peripheral blood lymphocyte subgroups in patients
infected with H1N1 swine-origin influenza A virus (S-OIV).
Methods: The frequency of T cells, B cells, natural killer (NK) cells, and regulatory T cells (Treg) in 36 severe H1N1
and 40 moderate H1N1 patients were detected at different periods by flow cytometry. In parallel, serum cytokines
were detected by enzyme-linked immunosorbent assay and C-reactive protein (CRP) was analyzed through an
image-type automatic biochemical analyzer. In addition, 20 healthy volunteers, who were not infected with 2009
H1N1 virus, were selected as controls.
Results: The frequency of NK cells were decreased in all cases and CD19
+ B cells were increased in severe cases
than those of the controls. At 1-2d from onset, the frequency of CD4
+ and CD4
+CD25
+ T cells in moderate cases
was higher than in the severe cases. Serum cytokines, specifically IL-2, IL-4, IL-6, IL-10, and IFN-g exhibited no
significant change both in the moderate and the severe cases during the whole monitoring process. In the early
stage of the disease, serum CRP levels in the severe and moderate groups were significantly higher than that in
the control group.
Conclusions: Patients showed different lymphocyte subgroup distributions between mild and severe cases, which
might affect the incidence and development of 2009 H1N1.
Background
T h el a t e s tp u b l i cd a t af r o mt h eC h i n e s eM i n i s t r yo f
Health showed 120,940 confirmed H1N1 cases and 659
deaths were reported from the Chinese mainland as of
January 2, 2010. Data analysis suggests that patients with
chronic diseases, obese patients, and pregnant women
are more liable to develop severe H1N1 influenza. After
initial infection by the virus, the host innate immune sys-
tem, as a first line of defense, takes protective measures
earlier than the adaptive immune system to avoid further
viral invasion or replication [1]. Animal experiments indi-
cated that when the swine-origin influenza A virus
(S-OIV) infected early hosts, it elicited strong CD4
+,
CD8
+,a n dC D 4
+CD25
+ T cell reactions [2]. CD4
+ and
CD8
+ T cells are related to viral immunity and the lack
of these cells would lead to a delay in viral clearance and
an increase in mortality [3-5]. On the other hand,
CD4
+CD25
+ cells are T cell subsets with an immune
inhibition function and could play an important regula-
tory role in a variety of infectious diseases [6-8]. These
complex molecular and cellular mechanisms are helpful
in controlling and eliminating the acute stage of viral
infection. Although successfully eliminating the virus is
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hosts could also result in tissue damage and autoimmune
responses. Therefore, monitoring the variation of cellular
immune functions in H1N1 patients have important clin-
ical significance. The aim of this study is to analyze the
dynamic fluctuations of T cells, B cells, natural killer
(NK) cells, and regulatory T cells in patients infected
with novel influenza H1N1, as well as serum cytokines
and C-reactive protein (CRP).
Methods
Enrollment of study subjects
Up to 76 H1N1 outpatients and inpatients were chosen
from August to December 2009 in the Department of
Infectious Diseases, First Affiliated Hospital, School of
Medicine, Zhejiang University. Among these, 36 cases
were severe and 40 cases were moderate (Table 1). In
addition, 20 healthy volunteers who were not infected
with 2009 H1N1 virus, were selected as controls. There
were no statistical differences between their ages and gen-
ders compared with the H1N1 patients.
T h ed i a g n o s t i cc r i t e r i af o rH 1 N 1w e r eb a s e do nt h e
I n f l u e n z aAH 1 N 1F l uC l i n i cP r o g r a m( p i l o tv e r s i o no f
the second edition, 2009) released by the Chinese Minis-
try of Health in July 2009. Its main content includes the
following:
I. Confirmation standard of Influenza A (H1N1) cases:
Patients are considered to have contracted the virus if
they present with influenza-like clinical manifestations
and had one or more of the following laboratory test
results: (1) Positive for S-OIV nucleic acid (through
real-time RT-PCR and RT-PCR); (2) S-OIV is isolated
and attained; and (3) Specific neutralizing antibody titers
for serum S-OIV are increased four times or more.
II. Severe cases: When confirmed or suspected cases
manifest one of the following signs, they are considered
as severe: (1) Complicated pneumonia with or without
hypoxemia and respiratory failure; (2) toxic shock; and
(3) multiple organ dysfunction syndrome or multiple
organ failure.
The study protocol was approved by the Ethics Review
Committee of the First Affiliated Hospital, School of
Medicine, Zhejiang University. All subjects understood
the procedures and consented participate in the study.
Sample collection and analysis
O nd a y1 ,2 ,3 ,5 ,7 ,9 ,1 1 ,1 4 ,a n d2 1 ,2m Lo fw h o l e
blood (EDTA-K2 anticoagulant) and 1.5 mL of serum
were collected from H1N1 patients for the detection
of lymphocyte subgroups, cytokines, and CRP. The
same sample collection was carried out in the control
group.
Table 1 Basic characteristic of patients with severe H1N1and moderate H1N1
Variable severe H1N1 (n = 36) moderate H1N1 (n = 40) P-value
Age, mean ± SD, years* 40.1 ±18.6 26.1 ± 8.0 0.006
Male/Female distribution, N (%)
▲ 20/25(55%/45%) 20/20(50%/50%) 0.653
Prodromal symptoms, N (%)
▲
Fever(T > 38.5) 28(78) 16(40) 0.001
Cough 26(72) 28(70) 1.000
Dyspnea 13(36) 0 <0.001
Gastrointestinal 4(11) 3(7) 0.702
Myalgia 23(64) 10(25) 0.001
Co-morbidities, N (%)
▲
COPD 12(33) 0 <0.001
Coronary artery disease 4(11) 0 <0.001
Diabetes mellitus 5(14) 2(5) 0.246
Hypertension 5(14) 2(5) 0.246
Pregnancy 4(11) 1(2.5) 0.131
Others (Hypothyroidism, Immunosuppression, Transplant) 3(8) 0 0.102
Changes in lung imaging examination, N (%)
▲ 20(55) 3(7) <0.001
Patients using Oseltamivir, N (%)
▲ 36(100) 40(100) 1.000
Oseltamivir treatment time, mean ± SD, (days)* 8.55 ± 3.39 3.60 ± 1.00 <0.001
Patients using combined glucocorticoid, N (%)
▲ 19(53) 0 <0.001
The number of people using the ventilato, N (%)
▲ 5(14) 0 <0.001
Average stay, mean ± SD, days* 13.71 ± 4.77 3.37 ± 1.06 <0.001
Death toll, N (%)
▲ 1(3) 0 0.474
Note: SD = standard deviation; COPD = chronic obstructive pulmonary disease. * Date are reported as mean ± SD;
▲ Date are expressed as no. (%).
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Page 2 of 6Afterwards, 100 μL of anticoagulant was added into all
flow tubes and 20 μL of CD3-PC5, CD4-FITC, CD8-PE,
CD3-FITC-CD(16+56)-PE, CD19-FITC, and CD25-PE
mouse anti-human fluorescence monoclonal antibodies
(BD Bioscience) was added. After mixing, the samples
were incubated for 15 min away from light at room
temperature. Red blood cell lysis and cell fixation using
Coulter QPREP specimen processing instrument (Beck-
man Coulter Inc., USA) was conducted, and the cells
more than 1 × 10
4 were counted through a flow cyt-
ometer (Coulter Cytomics FC 500, Beckman Coulter).
The results were expressed as the percentages of CD4
+CD25
+,C D 4
+,a n dC D 8
+ Tc e l l s ,a sw e l la st h o s eo f
CD19
+ B cells and NK (marked as CD3
-CD16
+CD56
+)
cells found positive for the antigen marker in the total
lymphocytes population. The data were collected and
analyzed using the EXPO32 software (Beckman Coulter
Inc., USA).
Serum CRP detection was conducted using the image-
type automatic biochemical analyzer (Beckman Coulter
Inc., USA). The kit was also provided by the same com-
pany. Serum cytokines, namely IL-2, IL-4, IL-6, IL-10, and
IFN-g were tested using an enzyme-linked immunosorbent
assay (ELISA; Ex-cell). The experimental methods were in
accordance with the instructions of the manufacturer in
the reagent kit.
Statistical analysis
SPSS 13.0 statistical package was used for data proces-
sing. Measurement data were indicated as mean ± stan-
dard deviation or percentages. Comparisons among
groups were carried out using one-way ANOVA or c
2
test. Differences with P < 0.05 were considered statisti-
cally significant. Correlation analysis among the detec-
tion indicators were conducted using Spearman’sr a n k
correlation analysis.
Results
Demographic characteristics and clinical features of H1N1
Up to 76 patients with confirmed laboratory diagnoses of
influenza were enrolled in this study. The baseline char-
acteristics of the patients are summarized in Table 1. The
samples were predominantly composed of full-grown
adults with S-OVI infection.
As shown in Table 1, the patients with severe H1N1
were significantly older than those that presented with
moderate H1N1 (mean age, 40.1 years vs. 26.1 years; P <
0.01). The mean duration of symptoms before presenta-
t i o nw a s4d a y s ,w i t hf e v e r ,c o u g h ,a n dm y a l g i aa st h e
most common in both groups. However, the patients with
severe H1N1 had more prodromal symptoms (e.g., fever,
dyspnea, and myalgia) and co-morbidities [e.g., chronic
obstructive pulmonary disease (COPD) and coronary
artery disease] than the patients with moderate H1N1 (p <
0.01). Although a relationship with pregnancy was more
common in the severe H1N1 group (four patients vs. one
patient with moderate H1N1), this difference was not sta-
tistically significant (Table 1). Similarly, there was no dif-
ference in the other preexisting diseases such as diabetes
mellitus and hypertension between the two groups.
Chest x-rays were taken from all patients, and
abnormalities were detected in 23 patients, 3 with mod-
erate H1N1 and 20 with severe H1N1. Ten patients pre-
sented with radiological abnormalities attributable to
chronic lung conditions without evidence of concurrent
pneumonia.
Up to 15 patients with severe H1N1 were admitted to
the intensive care unit (ICU) with preexisting diseases,
such as COPD. All patients were treated with Oseltamivir
(Tamiflu) and 53% of the severe H1N1 patients were addi-
tionally treated with glucocorticoids (19/36). The duration
of Oseltamivir treatment was based on the Pandemic
Influenza A (H1N1) 2009 Clinical Guidelines (Second
Edition, 2009). However, the subjects were not given
immunomodulators. Treatment response did not differ
significantly between the two groups and the mean dura-
tion of hospital confinement was 13.7 days (range, 0-51
days) and 3.3 days (range, 0-11 days) for the severe and
moderate patients, respectively. Overall, only one severe
H1N1 patient died during the course of the study.
No patient dropped out and all completed the 21-week
follow-up.
Peripheral blood lymphocyte subgroups changes
The frequency of peripheral blood CD19
+ B cell count of
patients with severe H1N1 gradually increased within the
first 3-14 d of treatment. The NK cell count showed a gra-
dual decline, whereas the T cell subtypes (CD4
+CD25
+,
CD4
+,a n dC D 8
+ T cells) showed no significant changes.
The frequency of peripheral CD4
+T and CD4
+CD25
+Treg
cells of patients with moderate H1N1 were significantly
higher than in patients with severe H1N1 within the first
1-2 d of treatment. The NK cell counts of patients with
moderate H1N1 were similar to that of patients with
severe H1N1, which demonstrated a gradual decline,
whereas the frequency of CD19
+ Ba n dC D 8
+ T cells
showed no significant changes.
The frequency of the different lymphocyte subsets at
different periods were statistically compared and the
results show that the frequency of peripheral CD4
+ and
CD4
+CD25
+ T cells in the moderate H1N1 patients were
higher than that of the severe H1N1 patients within the
first 1-2 d (Figures 1a and 1c; P < 0.05). The CD19
+ B
cell counts of the severe H1N1 patients were significantly
higher than those of the moderate H1N1 patients and the
control group for the same period (Figure 1e), whereas
the NK cell counts were significantly less than that of the
control group (Figure 1d; P < 0.05). The frequency of
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+ T cells had no significant difference (P > 0.05; Fig-
ure 1b) among the three groups.
Behavior of the serum CRP responses against a sustained
treatment
In the first 1-5 d of study, the serum CRP levels of both
the patients with severe H1N1 and the patients with
moderate H1N1 were significantly higher than that of
the control group (P < 0.01; Figure 1f). Correlation ana-
lysis of the CD4
+,C D 8
+ T, CD4
+CD25
+, CD19
+ B, and
NK cells with CRP was conducted and the results indi-
cate that the various lymphocyte subgroups had no sig-
nificant correlations with CRP.
Induction of serum cytokines activity
The serum cytokines of patients, specifically IL-2, IL-4,
IL-6, IL-10, and IFN-g, whether the H1N1 infection was
severe or moderate, showed no significant changes dur-
ing the whole monitoring process (data not shown). The
differences of the H1N1 patients with the control group
had no statistical significance.
Discussion
Influenza A (H1N1) is the greatest pandemic threat in
2009 [9]. The clinical course of H1N1 can be severe,
particularly for very young patients with complica-
tions. The immune response affected by pathological
damage to the body caused by S-OVI and clinical
prognosis. Studies have shown that the incidence of
patients with severe H1N1 was highest in the 15- to
19-year-old age group and the lowest for patients aged
65 or above [10]. Our clinical data also showed that
the most severe infections occur in individuals
younger than 25 years old or in middle-aged patients
Figure 1 Analysis of the dynamic changes in the lymphocyte subgroup and C-reactive protein (CRP) in the peripheral blood of
patients with Influenza A (H1N1) 2009. CD4
+ T, CD8
+ T, CD4
+CD25
+ Treg, NK, and CD19
+ B cells are presented as a percentage of total
peripheral blood leukocytes (PBLs) in severe H1N1 (n = 36) patients, moderate H1N1 (n = 40) patients, and healthy volunteers (n = 20). †:
denotes statistically significant differences compared with severe H1N1; *: denotes statistically significant differences compared with the healthy
volunteers; **: denotes statistically significant differences compared with the moderate H1N1 patients and with the healthy volunteers.
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lung disease.
Based on local guidelines, antiviral treatment would be
considered for severe or critical cases and high-risk
patients infected with the influenza A pandemic (H1N1)
virus within 48 h of onset. For patients who presented
later than 2 days, the managing physicians were allowed
to make decisions regarding antiviral use. Oseltamivir,
given to patients older than 12 years, was prescribed
according to the standard dosing regimen (75 mg twice
daily orally, for 5 days). Dosage adjustment, whenever
necessary, were based on the patient’s renal function (75
mg daily, if creatinine clearance is <30 mL/min). For
children (1-12 years old), dosage adjustments were
based on body weight (BW), that is: 30 mg twice daily
for children with BW < 15 kg; 45 mg twice daily for
BW 15-23 kg; 60 mg twice daily for BW 23-40 kg; and
75 mg twice daily for BW > 40 kg. Accordingly, patients
with acute respiratory distress syndrome (ARDS) were
treated with high dose glucocorticoids over a short per-
iod of time, which has been proven beneficial and safe.
Several lines of experimental evidence suggest that
H1N1 infections accompanied by a characteristic
impairment of the innate immune response. By moni-
toring the host functional response, patients with
increased risks of developing severe influenza-associated
complications could be identified immediately [11,12].
T h ep r e l i m i n a r yd a t af r o mt h i ss t u d ys h o w e dt h a tt h e
frequency of CD19
+ B cells in patients with severe
H1N1 was significantly higher than in the moderate and
control groups (Figure 1e), and the frequency of NK
cells in the severe and moderate groups were less than
that of the control group. In the host innate immune
system, NK cells are the major effector cells during
acute infection, rapidly killing infected cells in the pro-
cess. Previous studies have shown that the significant
decrease in peripheral NK cell count is mainly because
the S-OVI directly infected and killed NK cells, thereby
limiting their activity and leading to their apoptosis in
vivo [13].
Animal studies have found that CD4
+ T, CD8
+ T, and
CD19
+ B cells achieved peak values within 5-6 d after S-
OVI infection, whereas the CD4
+CD25
+ Treg cell count
reached its peak at 24-48 h after infection [2]. Currently,
the use of flow cytometric analysis to measure periph-
eral blood CD4
+,C D 8
+,a n dC D 4
+CD25
+ T cells is a
simple and common method. Reportedly, the mostly
CD4
+CD25
+ T cells were also positive for FoxP3 [14].
In this experiment, the peak values for all lymphocyte
subgroups in patients with severe H1N1 could not be
detected. At least two mechanisms could account for
the lower effector T cell response detected after the S-
OVI infection, and the peak response time for the
effector T cells possibly missed. In addition, the virus
could have also led to the immunotolerance of the T
cells [15].
As intercellular signaling molecules, cytokines regulate
the immune response, mediate inflammatory responses,
and participate in tissue repair. Experiments have shown
that only the peak values of IFN-a and IL-6 could
respectively be detected within 24 and 30 h in the
serum of infected animals, as well as in the plasma of
pediatric patients with severe influenza [16,17]. In this
experiment, no statistically significant changes were
found during the continuous monitoring of serum IL-2,
IL-4, IL-6, IL-10, and IFN-g of patients with severe and
moderate H1N1, as well as in the control group. This
result might also be related to the immunotolerance of
T cells, of which the peak detection might have been
missed. The mechanisms responsible for maintaining
these relatively constant levels remain unclear.
CRP is an acute phase protein produced by the liver
and is a sensitive marker for the inflammatory response.
It did not directly related to viral load [17]. However,
CRP continuously increased in the initial stages of infec-
tion for both the patients with severe and those with
moderate H1N1. The CRP of patients with severe H1N1
took longer to return to normal, which might be the
result of underlying disease. Each lymphocyte subgroup
has made correlatively analyzed with CRP and the
results show no significant correlations.
In conclusion, S-OIV could stimulate the cellular
immune response. When accompanied by CD19
+ Bc e l l
increase and a continuous NK cell decline, it could indi-
cate that the body is in a dynamic balance of the anti-
infection immunity and autoimmune damage; this is
particularly true for patients with severe influenza. Each
lymphocyte subgroup in patients with H1N1 plays a
more important antiviral role in the early stages of dis-
ease, but excessive immune response also leads to the
increase and development of infection.
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